 11. Has received prior therapy with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCytotoxic Tlymphocyteassociated antigen4 CTLA4 antibody including ipilimumab or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways. 